Jeff Yass’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-721,200
| Closed | -$24.1M | – | 14434 |
|
|
2026
Q1 | $24.1M | Buy |
721,200
+363,900
| +102% | +$14.3M | ﹤0.01% | 1981 |
|
|
2025
Q4 | $16.5M | Sell |
357,300
-64,000
| -15% | -$3.51M | ﹤0.01% | 2413 |
|
|
2025
Q3 | $28.5M | Sell |
421,300
-338,600
| -45% | -$25.1M | ﹤0.01% | 1847 |
|
|
2025
Q2 | $63.7M | Buy |
759,900
+452,800
| +147% | +$33.9M | 0.01% | 1006 |
|
|
2025
Q1 | $21.9M | Sell |
307,100
-1,203,900
| -80% | -$58.6M | ﹤0.01% | 1666 |
|
|
2024
Q4 | $67.9M | Buy |
1,511,000
+1,441,400
| +2,071% | +$74.7M | 0.01% | 921 |
|
|
2024
Q3 | $3.51M | Sell |
69,600
-42,800
| -38% | -$2.05M | ﹤0.01% | 4244 |
|
|
2024
Q2 | $4.59M | Buy |
112,400
+93,400
| +492% | +$3.96M | ﹤0.01% | 3590 |
|
|
2024
Q1 | $813K | Sell |
19,000
-38,400
| -67% | -$1.74M | ﹤0.01% | 7374 |
|
|
2023
Q4 | $2.31M | Buy |
+57,400
| New | +$1.63M | ﹤0.01% | 5068 |
|
|
2022
Q4 | – | Sell |
-14,500
| Closed | -$24K | – | 13574 |
|
|
2022
Q3 | $24K | Buy |
14,500
+13,533
| +1,399% | +$33K | ﹤0.01% | 12535 |
|
|
2022
Q2 | $3K | Buy |
967
+34
| +4% | +$94 | ﹤0.01% | 12662 |
|
|
2022
Q1 | $3K | Sell |
933
-1,254
| -57% | -$6.49K | ﹤0.01% | 12854 |
|
|
2021
Q4 | $13K | Sell |
2,187
-7,286
| -77% | -$76.4K | ﹤0.01% | 12899 |
|
|
2021
Q3 | $131K | Sell |
9,473
-3,514
| -27% | -$49K | ﹤0.01% | 11888 |
|
|
2021
Q2 | $222K | Buy |
12,987
+8,447
| +186% | +$143K | ﹤0.01% | 11382 |
|
|
2021
Q1 | $86K | Buy |
4,540
+3,360
| +285% | +$108K | ﹤0.01% | 11908 |
|
|
2020
Q4 | $34K | Sell |
1,180
-147
| -11% | -$4.24K | ﹤0.01% | 10822 |
|
|
2020
Q3 | $50K | Buy |
1,327
+547
| +70% | +$16K | ﹤0.01% | 10200 |
|
|
2020
Q2 | $26K | Buy |
+780
| New | +$33.8K | ﹤0.01% | 9888 |
|
Jeff Yass's SLNO Position: Q2 2026 in Review
Jeff Yass sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 549,877 shares — an estimated $18.4M sold.
Jeff Yass first reported a position in SLNO in Q1 2017 and held it in 23 quarters. The position peaked at $34.6M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Jeff Yass reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Jeff Yass sold 549,877 Soleno Therapeutics shares in Q2 2026, an estimated $18.4M.
- Jeff Yass first reported a position in Soleno Therapeutics in Q1 2017 and held it in 23 quarters.
- Jeff Yass's Soleno Therapeutics position peaked at $34.6M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.